Genfit (NASDAQ:GNFT) and Qiagen (NYSE:QGEN) Critical Comparison

Genfit (NASDAQ:GNFT) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Profitability

This table compares Genfit and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Qiagen	4.23%	13.92%	8.40%

Valuation and Earnings

This table compares Genfit and Qiagen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$67.00 million	3.37	-$31.27 million	N/A	N/A
Qiagen	$2.00 billion	5.02	$83.59 million	$0.40	113.19

Qiagen has higher revenue and earnings than Genfit.

Risk & Volatility

Genfit has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Genfit and Qiagen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	1	0	3.00
Qiagen	0	7	3	0	2.30

Genfit currently has a consensus price target of $13.00, indicating a potential upside of 188.25%. Qiagen has a consensus price target of $48.42, indicating a potential upside of 6.94%. Given Genfit’s stronger consensus rating and higher probable upside, analysts clearly believe Genfit is more favorable than Qiagen.

Institutional and Insider Ownership

2.2% of Genfit shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Qiagen beats Genfit on 9 of the 12 factors compared between the two stocks.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.